Hostname: page-component-7479d7b7d-qlrfm Total loading time: 0 Render date: 2024-07-13T14:33:29.808Z Has data issue: false hasContentIssue false

Intratympanic gentamicin treatment for unilateral Ménière's disease: long-term follow up of a proven regime

Published online by Cambridge University Press:  07 December 2012

J Wasson*
Affiliation:
Department of Otolaryngology, Norfolk and Norwich University Hospital, UK
N Upile
Affiliation:
Department of Otolaryngology, Peterborough City Hospital, UK
A Pfleiderer
Affiliation:
Department of Otolaryngology, Peterborough City Hospital, UK
*
Address for correspondence: Mr J Wasson, 80 Tenison Rd, Cambridge CB1 2DW, UK E-mail: josephwasson@hotmail.com

Abstract

Objective:

To determine the long-term efficacy of a fixed-dose intratympanic gentamicin treatment regime in controlling unilateral Ménière's disease.

Methods:

Pfleiderer (1998) published two-year follow-up results for a series of 16 patients treated with a 4-day, 12-dose intratympanic gentamicin regime for unilateral Ménière's disease that was refractory to medical treatment. In 2010, a long-term telephone follow up (mean 17 years and 3 months) of this same cohort was conducted to determine long-term vertigo control. Of the 16 patients, 13 were eligible for the long-term follow up.

Results:

At 2 years' follow up, all 16 patients experienced substantial control of vertigo, with complete control achieved in 87 per cent of cases. At the long-term follow up, 9 of the 13 eligible patients were contactable, and all reported complete control of vertigo.

Conclusion:

Fixed-dose intratympanic gentamicin controlled symptomatic unilateral Ménière's disease in both the short and long term.

Type
Main Articles
Copyright
Copyright © JLO (1984) Limited 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 Schuknecht, HF. Ablation therapy in the management of Menière's disease. Acta Otolaryngol Suppl 1957;132:142 Google ScholarPubMed
2 Chia, SH, Gamst, AC, Anderson, JP, Harris, JP. Intratympanic gentamicin therapy for Ménière's disease: a meta-analysis. Otol Neurotol 2004;25:544–52CrossRefGoogle ScholarPubMed
3 Smith, WK, Sankar, V, Pfleiderer, AG. A national survey amongst UK otolaryngologists regarding the treatment of Ménière's disease. J Laryngol Otol 2005;119:102–5CrossRefGoogle ScholarPubMed
4 Nedzelski, JM, Schessel, DA, Bryce, GE, Pfleiderer, AG. Chemical labyrinthectomy: local application of gentamicin for the treatment of unilateral Menière's disease. Am J Otol 1992;13:1822 Google ScholarPubMed
5 Bodmer, D, Morong, S, Stewart, C, Alexander, A, Chen, JM, Nedzelski, JM. Long-term vertigo control in patients after intratympanic gentamicin instillation for Ménière's disease. Otol Neurotol 2007;28:1140–4CrossRefGoogle ScholarPubMed
6 Pfleiderer, AG. The current role of local intratympanic gentamicin therapy in the management of unilateral Menière's disease. Clin Otolaryngol Allied Sci 1998;23:3441 CrossRefGoogle ScholarPubMed
7 Alford, BR. Committee on Hearing and Equilibrium. Report of Subcommittee on Equilibrium and its Measurement: Meniere's disease: criteria for diagnosis and evaluation of therapy for reporting. Trans Am Acad Ophthalmol Otolaryngol 1972;76:1462–4Google Scholar
8 Cohen-Kerem, R, Kisilevsky, V, Einarson, TR, Kozer, E, Koren, G, Rutka, JA. Intratympanic gentamicin for Menière's disease: a meta-analysis. Laryngoscope 2004;114:2085–91CrossRefGoogle ScholarPubMed
9 Beck, C. Intratympanic application of gentamicin for treatment of Menière's disease. Keio J Med 1986;35:3641 CrossRefGoogle ScholarPubMed
10 Hone, WS, Nedzelski, J, Chen, J. Does intratympanic gentamicin treatment for Meniere's disease cause complete vestibular ablation? J Otolaryngol 2000;29:83–7Google ScholarPubMed